Miltefosine treatment of Leishmania major infection: An observational study involving dutch military personnel returning from northern Afghanistan

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 80-83

  Van Thiel, P P A M ^a,c   Leenstra, T ^a,c   Kager, P A ^a   De Vries, H J ^a   Van Vugt, M ^a   Van Der Meide, W F ^b,d   Bart, A ^a   Zeegelaar, J E ^a,e   Van Der Sluis, A ^c   Schallig, H D F H ^b   Van Gool, T ^a   Faber, W R ^a   De Vries, P J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

^c Ministerie van Defensie   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Flevoziekenhuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ANTIMONY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; MILTEFOSINE;

ABDOMINAL DISCOMFORT; ADULT; AFGHANISTAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; EOSINOPHILIA; EPIDIDYMITIS; ERECTILE DYSFUNCTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LEISHMANIA MAJOR; LEISHMANIASIS; LIBIDO DISORDER; MALE; NAUSEA; NETHERLANDS; NONHUMAN; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCROTUM DISORDER; SEXUALITY; SIDE EFFECT; SKIN LEISHMANIASIS; SOLDIER; SPERM; TREATMENT OUTCOME; VOMITING;

ADULT; AFGHANISTAN; FEMALE; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; MILITARY PERSONNEL; NETHERLANDS; PHOSPHORYLCHOLINE; RETROSPECTIVE STUDIES; TRAVEL; TREATMENT OUTCOME;

EID: 72049111032     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648726     Document Type: Article

References (22)

1. Croft SL, Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100(Suppl 1):S4-S8. (Pubitemid 44490168)
2. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-1746 (Pubitemid 35375612)
3. Stojkovic M, Junghans T, Krause E, Davidson RN. First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol 2007; 46:385-387 (Pubitemid 46585389)
4. Van der Meide W, de Vries H, Pratlong F, van der Wal A, Sabajo L. Leishmania (Leishmania) amazonensis Infection, Suriname. Emerg Infect Dis 2008; 14:857-859
5. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica 2007; 103:33-40. (Pubitemid 47078934)
6. Rahman SB, ul Bari A, Mumtaz N. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 2007; 17: 132-135
7. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 2008; 19:394-396
8. Soto J, Arana BA, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-1272
9. Soto J, Toledo J Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-356 (Pubitemid 46147616)
10. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210-211 (Pubitemid 351844550)
11. Faulde MK, Heyl G, Amirih ML. Zoonotic cutaneous leishmaniasis, Afghanistan. Emerg Infect Dis 2006; 12:1623-1624
12. González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane database of Systemic reviews 2008, Issue 4. Art. no.: CD005067. DOI:10.1002/14651858.CD005067.pub3.
13. Marfurt J, Nasereddin A, Niederwieser I, Jaffe CL, Beck HP, Felger I. Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol 2003; 41:3147-3153
14. Van der Meide WF, Schoone GJ, Faber WR, et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J Clin Microbiol 2005; 43:5560-5566
15. Dorlo TPC, van Thiel PPAM, Huitema ADR, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855-2860
16. 3 (edelfosine) and amphotericin B. Acta Tropica 2002; 81:151-157
17. Yardley V, Croft SL, De Doncker S, et al. The sensitivity of clinical isolates of LEISHMIA from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005; 73:272-275
18. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-364 (Pubitemid 44078909)
19. Dowlati Y. Cutaneous leishmaniasis: clinical aspects. Clin Dermatol 1996; 14:425-431
20. Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 2005; 6:1381-1388
21. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of leishmaniasis cause by Leishmania major. N Engl J Med 2002; 346: 891-895
22. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travellers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76:48-52.